CD274 and cancer: Durvalumab recognizes and attaches to the PD-1 receptor on T cells, and it competes with the secreted PD-L1/2 of cancer cells for attachment to the PD-1 receptor on T cells, thus preventing the cancer cells from shutting down the T cells through an immune escape mechanism; this enhances the ability of the immune system to destroy cancer cells.